Back to Search
Start Over
Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season.
- Source :
- Clinical Infectious Diseases; Dec2019, Vol. 69 Issue 11, p1845-1853, 9p
- Publication Year :
- 2019
-
Abstract
- Background The severity of the 2017–2018 influenza season in the United States was high, with influenza A(H3N2) viruses predominating. Here, we report influenza vaccine effectiveness (VE) and estimate the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the 2017–2018 influenza season. Methods We used national age-specific estimates of 2017–2018 influenza vaccine coverage and disease burden. We estimated VE against medically attended reverse-transcription polymerase chain reaction–confirmed influenza virus infection in the ambulatory setting using a test-negative design. We used a compartmental model to estimate numbers of influenza-associated outcomes prevented by vaccination. Results The VE against outpatient, medically attended, laboratory-confirmed influenza was 38% (95% confidence interval [CI], 31%–43%), including 22% (95% CI, 12%–31%) against influenza A(H3N2), 62% (95% CI, 50%–71%) against influenza A(H1N1)pdm09, and 50% (95% CI, 41%–57%) against influenza B. We estimated that influenza vaccination prevented 7.1 million (95% CrI, 5.4 million–9.3 million) illnesses, 3.7 million (95% CrI, 2.8 million–4.9 million) medical visits, 109 000 (95% CrI, 39 000–231 000) hospitalizations, and 8000 (95% credible interval [CrI], 1100–21 000) deaths. Vaccination prevented 10% of expected hospitalizations overall and 41% among young children (6 months–4 years). Conclusions Despite 38% VE, influenza vaccination reduced a substantial burden of influenza-associated illness, medical visits, hospitalizations, and deaths in the United States during the 2017–2018 season. Our results demonstrate the benefit of current influenza vaccination and the need for improved vaccines. [ABSTRACT FROM AUTHOR]
- Subjects :
- MORTALITY prevention
MORTALITY risk factors
MORTALITY
VACCINATION
CONFIDENCE intervals
CLINICAL pathology
HOSPITAL care
INFLUENZA vaccines
INFLUENZA A virus, H3N2 subtype
MEDICAL appointments
PEDIATRICS
POLYMERASE chain reaction
TREATMENT effectiveness
INFLUENZA B virus
INFLUENZA A virus, H1N1 subtype
SEASONAL influenza
CHILDREN
Subjects
Details
- Language :
- English
- ISSN :
- 10584838
- Volume :
- 69
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Clinical Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 139643696
- Full Text :
- https://doi.org/10.1093/cid/ciz075